research use only
Cat.No.E0363
| Related Targets | HDAC Caspase Proteasome MMP HCV Protease Cysteine Protease DPP Tyrosinase HIV Protease Serine Protease |
|---|---|
| Other Secretase Inhibitors | DAPT LY411575 Nirogacestat (PF-03084014) RO4929097 (RG-4733) DBZ (Dibenzazepine) Avagacestat (BMS-708163) MK-0752 Semagacestat (LY450139) MDL-28170 L-685,458 |
|
In vitro |
DMSO
: 44 mg/mL
(199.79 mM)
Ethanol : 4 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 220.23 | Formula | C10H12N4O2 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 842964-18-5 | -- | Storage of Stock Solutions |
|
|
| Targets/IC50/Ki |
Secretase
(in fluorescence-based assay) 0.7 μM
δ-secretase
(in Pala cells assay) 0.8 μM
|
|---|---|
| In vitro |
Compound 11 inhibit δ-secretase in Pala cells, with an IC50 of 7 μM. Compounds 11 is highly permeable assessed by Caco-2 monolayer permeability screen. The human liver microsomal stability screen demonstrates that following 30 min of incubation, 76% of compound 11 remained in human liver microsomes. |
| In vivo |
Chronic treatment with δ-secretase inhibitor 11 markedly decreases the brain asparaginyl endopeptidase (AEP) activity, reduces the generation of Aβ1-40/42 and ameliorates memory loss. The inhibition of AEP with this reagent not only reduces the AEP-cleaved tau fragments and tau hyperphosphorylation, but also attenuates neuroinflammation in the form of microglial activation. Treatment with δ-secretase inhibitor 11 prevents the synaptic loss and alleviated dendritic disruption in senescence-accelerated mouse prone 8 (SAMP8) mouse brain. |
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.